Phase III Seattle Genetics discontinued the Phase III CASCADE Trial of Vadastuximab Talirine in Front-Line AML in June 2017. Regulatory decisions EMA Orphan drug designation in Acute Myeloid Leukemia (AML), August 10, 2015 CAS 1436390-64-5 UNII (FDA) T13V17U431 Drug description A CD33 direc...